RE:RE:That top 10 pharma?J & J is not interested in another meetoo SGLT2, they have Canagliflozin, first to market but second in market share behind Empagliflozin, then Dapaglifozin is a far distant 3rd. Cana dropped to second because of less efficacious endpoint data on Renal and CV outcomes in their trials. But patterns of practice are changing and now their is prophylaxis use with this class. But that is beside the point, as I mentioned a few months ago J & J discontinued their skin lightner earlier this year and may be interested in a a replacement. They are a published evidenced based company with very deep coffers and is the number one Pharma company in the world. That is what I am betting on, not Howie et al